コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 define the role of these molecules during P. vivax malaria.
2 croscopy (the gold standard) for detecting P vivax malaria.
3 exploited to develop therapeutics against P. vivax malaria.
4 igated antimalarial treatment efficacy in P. vivax malaria.
5 stage parasite clearance of uncomplicated P. vivax malaria.
6 bodies remain uncharacterized for Plasmodium vivax malaria.
7 t factors in the provocation of a relapse of vivax malaria.
8 cule an attractive vaccine candidate against vivax malaria.
9 pment of a broadly effective vaccine against vivax malaria.
10 ot be the only cause of recurrent Plasmodium vivax malaria.
11 pregnancy-associated malaria, and Plasmodium vivax malaria.
12 he treatment of Plasmodium falciparum and P. vivax malaria.
13 , would confer a selective advantage against vivax malaria.
14 cond-generation vaccine candidate against P. vivax malaria.
15 ccine for antibody-mediated immunity against vivax malaria.
16 antibodies in protective immunity against P. vivax malaria.
17 primaquine effectively prevents relapses of vivax malaria.
18 rophylaxis agents do not prevent relapses of vivax malaria.
19 age parasites isolated from patients with P. vivax malaria.
20 tiveness of primaquine for radical cure of P vivax malaria.
21 on people live with the threat of Plasmodium vivax malaria.
22 12.4 (10.7-14.8) million clinical cases of P vivax malaria.
23 reduced to a greater extent than that of P. vivax malaria.
24 d colleagues explore efforts to eliminate P. vivax malaria.
25 total parasite biomass and host response in vivax malaria.
26 treatment to prevent relapses of Plasmodium vivax malaria.
27 nse and a promising vaccine candidate for P. vivax malaria.
28 s White introduce a Collection on Plasmodium vivax malaria.
29 rovide durable and potent protection from P. vivax malaria.
30 y recommended for patients presenting with P vivax malaria.
31 ivation (ICAM-1, angiopoietin-2) and ADMA in vivax malaria.
32 rial drug for the radical cure of Plasmodium vivax malaria.
33 used drug for the radical cure of Plasmodium vivax malaria.
34 of their protection from endemic Plasmodium vivax malaria.
35 using PvRBP2a as a vaccine target against P. vivax malaria.
36 o simultaneously combat P. falciparum and P. vivax malaria.
37 proportional protective effect against acute vivax malaria.
38 eness of primaquine for reducing relapses of vivax malaria.
39 C-D) is not well characterized in Plasmodium vivax malaria.
40 e (7 days) of primaquine for radical cure of vivax malaria.
41 r clinical development as a treatment for P. vivax malaria.
42 (PQ)-based radical cure for the treatment of vivax malaria.
43 mparisons with controls) and were highest in vivax malaria.
44 equently, our ability to effectively control vivax malaria.
45 parasites (hypnozoites) are a major cause of vivax malaria.
46 ent of new therapeutic interventions against vivax malaria.
47 levels correlate with protection against P. vivax malaria.
48 Anemia is a major complication of vivax malaria.
49 development of blood stage vaccines against vivax malaria.
50 een has been reported in cases of Plasmodium vivax malaria.
51 ng-inhibitory antibodies through exposure to vivax malaria.
52 he only drug available to prevent relapse in vivax malaria.
53 oites and, therefore, preventing relapses of vivax malaria.
54 he development of an efficacious vaccine for vivax malaria.
55 exploited to develop therapeutics against P. vivax malaria.
56 vaccines and effective treatments to combat vivax malaria.
57 n Southeast Asia, provides a barrier against vivax malaria.
58 8; p=0.0473) following recurrent symptomatic vivax malaria.
59 the most promising vaccine candidate for P. vivax malaria.
60 he next generation of potent vaccines for P. vivax malaria.
61 alaria, but have not been assessed in severe vivax malaria.
62 asitaemia rapidly in both P falciparum and P vivax malaria.
63 nts with Plasmodium falciparum or Plasmodium vivax malaria.
64 -0.34 to -0.07]) but not in patients with P. vivax malaria (0.28% [21/7,545] versus 0.23% [28/12,397]
65 tial cohorts of adults with uncomplicated P. vivax malaria (10 patients) or P. falciparum malaria (11
66 evere vivax malaria as compared to nonsevere vivax malaria (2.5 vs 1 g/dL; P = .0001), markers of int
67 ctive was to study whether people exposed to vivax malaria acquire antibodies that have the ability t
68 e showed efficacy for the radical cure of P. vivax malaria, although tafenoquine was not shown to be
69 range, 0.85 to 1.14) in the patients with P. vivax malaria and 0.90 hours (range, 0.68 to 1.64; inter
70 ile range, 8 to 16 hours in patients with P. vivax malaria and 10 to 16 hours in those with P. falcip
72 al (CI) 0.19% to 2.57%] in all patients with vivax malaria and 7.11% [95% CI 4.30% to 11.55%] in hosp
73 the radical curative treatment of Plasmodium vivax malaria and can cause haemolysis in G6PD deficient
75 e a better understanding of the pathology of vivax malaria and development of antimalarial drugs and
76 We quantified the global economic cost of vivax malaria and estimated the potential cost benefit o
77 e and discuss the estimated global burden of vivax malaria and it's biological, clinical, and public
78 temporal epidemiological cases of Plasmodium vivax malaria and land-use irrigation from remote sensin
82 bility) were reduced in patients with severe vivax malaria and those with nonsevere vivax malaria, co
83 lyx degradation is increased in knowlesi and vivax malaria, and associated with disease severity and
84 h severe vivax malaria, those with nonsevere vivax malaria, and healthy controls, respectively; P = .
85 ly vulnerable to adverse clinical impacts of vivax malaria, and preventing infections and relapse in
89 ficant illness in travelers, but relapses of vivax malaria are not prevented with the current first-l
90 lopment of vaccines and drugs for Plasmodium vivax malaria are the inability to culture this species
92 ll in hemoglobin level was greater in severe vivax malaria as compared to nonsevere vivax malaria (2.
93 plasma from populations naturally exposed to vivax malaria, as well as antisera obtained by vaccinati
94 in plasmas from people naturally exposed to vivax malaria, as well as in antisera obtained by animal
96 nsities and the frequency distribution of P. vivax malaria attacks experienced by each individual ove
97 20 of 3883 patients (21.1%) had recurrent P. vivax malaria before 2010, compared with 22 of 886 (2.5%
101 CQ were effective and well-tolerated for P. vivax malaria, but high rates of recurrent parasitemia w
102 necessary for the radical cure of Plasmodium vivax malaria, but the optimum duration of treatment and
103 cation of acute Plasmodium falciparum and P. vivax malaria, but the risk of splenic rupture in chroni
106 However, the increasing number of reports of vivax malaria cases in genotypically Duffy-negative (DN)
107 ctions in children in endemic areas, in whom vivax malaria causes increased morbidity and mortality a
111 were increased in patients with knowlesi and vivax malaria compared to healthy controls, and in knowl
112 ity of which were uninfected, was reduced in vivax malaria compared with controls (n = 15), though no
114 evere vivax malaria and those with nonsevere vivax malaria, compared with healthy controls (median L-
117 mic downturn, difficulties in elimination of vivax malaria, development of pyrethroid resistance in s
118 tics are necessary for preventing Plasmodium vivax malaria due to easy transmissibility and dormancy
123 CI 0.48-0.49]), whereas the incidence of P. vivax malaria fell from 331 to 239 per 1,000 py (IRR = 0
126 stantial evidence of severe presentations of vivax malaria has accrued over the last 10 years, but re
127 a, where elimination of P. falciparum and P. vivax malaria has been the focus of control efforts.
130 oquine, a single-dose therapy for Plasmodium vivax malaria, has been associated with relapse preventi
131 sumptive antirelapse treatment of Plasmodium vivax malaria, has shown activity against Babesia microt
132 Reports of the severe clinical impacts of vivax malaria have been increasing over the last decade.
134 small size of most of the studies of severe vivax malaria, high heterogeneity of included studies wh
135 of inhibitory receptors on T cells during P. vivax malaria impairs parasite-specific T-cell effector
137 se of rhino-orbital mucormycosis following P.vivax malaria in a 20-year-old female with anemia and th
138 ew insight into the history and status of P. vivax malaria in Africa and efforts geared toward its er
139 is recommended for uncomplicated Plasmodium vivax malaria in areas of emerging chloroquine resistanc
140 primaquine regimens to prevent relapse of P. vivax malaria in children at least 5 years of age and in
141 How much they contribute to the burden of P. vivax malaria in children living in highly endemic areas
144 e is the first-line treatment for Plasmodium vivax malaria in most endemic countries, but resistance
149 the risk of re-presentation to hospital with vivax malaria in patients prescribed dihydroartemisinin-
156 decrease in the prospective risk of clinical vivax malaria in subjects with the strongest BIAb respon
158 sion models simultaneously to age-stratified vivax malaria incidence densities and the frequency dist
159 associated with reductions in symptomatic P. vivax malaria incidence of 76% (95% credible interval [C
160 RBC-D may contribute to the pathogenesis of vivax malaria, including splenic retention of uninfected
161 We describe the main clinical impacts of vivax malaria, incorporating a rapid systematic review o
164 ipheral blood origin of recurrent Plasmodium vivax malaria is both hypnozoites (relapse source) and m
166 rtantly, in some parts of the globe where P. vivax malaria is endemic, as many as 90% of P. vivax blo
167 Effective control strategies targeting P. vivax malaria is hindered by our limited understanding o
171 d treatment to prevent relapse of Plasmodium vivax malaria is primaquine at a total dose of 3.5 mg pe
174 function is impaired in nonsevere and severe vivax malaria, is associated with reduced L-arginine bio
176 y against some of the virulent effects of P. vivax malaria may be built up over the course of many in
177 6 months with parasitologically confirmed P vivax malaria mono-infection or P vivax plus P falciparu
178 efficacy studies of acute, uncomplicated P. vivax malaria mono-infections treated with radical curat
181 vax malaria (n = 9), patients with nonsevere vivax malaria (n = 58), and healthy controls (n = 79), w
184 nistration of primaquine for treatment of P. vivax malaria needs to be urgently considered to prevent
186 13, there were 86,797 documented episodes of vivax malaria, of which 62,492 (72.0%) were included in
187 P. vivax on BS; 2 received a diagnosis of P. vivax malaria on the basis of RDT but BSs were negative;
189 een associated with protection from clinical vivax malaria or reduced Plasmodium vivax density, inclu
194 t increased risk of death from falciparum or vivax malaria, particularly in those with concurrent sev
195 nses against all PvTRAgs in the sera from 96 vivax malaria patients and 40 healthy individuals using
196 rict, Ethiopia, Plasmodium falciparum and P. vivax malaria patients and controls were examined, toget
197 the serum proteome alterations in non-severe vivax malaria patients before and during patient recuper
199 host signatures in a cohort of uncomplicated vivax malaria patients from Manaus, Brazil, combining cl
200 lated with our observations in a panel of 50 vivax malaria patients where schizonts were completely a
201 t comprehensive serum proteomics analysis of vivax malaria patients with different levels of parasite
202 is to compare the serum proteome profiles of vivax malaria patients with low (LPVM) and moderately-hi
203 compared different treatment regimens for P. vivax malaria, patients with a normal standard NADPH flu
206 tors on Plasmodium falciparum and Plasmodium vivax malaria presence at the community level in Africa
208 with acute, uncomplicated P falciparum or P vivax malaria received artefenomel in a single oral dose
209 es of chloroquine resistance according to P. vivax malaria recurrence rates by day 28 whole-blood chl
211 Some data lend support to the notion that vivax malaria relapse followed febrile illness caused by
212 300 mg coadministered with chloroquine for P vivax malaria relapse prevention was more efficacious th
214 ly widely used drug that prevents Plasmodium vivax malaria relapses, but adherence to the standard 14
219 terventions that will reduce transmission of vivax malaria requires knowledge of Plasmodium vivax gam
221 laria convened the first malaria conference, Vivax Malaria Research: 2002 and Beyond, devoted entirel
223 e FY*O allele confers complete resistance to vivax malaria, suggesting that this allele has been the
224 higher efficacy in preventing relapse of P. vivax malaria than a total dose of 3.5 mg per kilogram t
226 ghts a substantial global economic burden of vivax malaria that could be reduced through investment i
227 1.49, 1.73, and 1.97 in patients with severe vivax malaria, those with nonsevere vivax malaria, and h
228 million cases and reduce the global cost of vivax malaria to US$266 million (95% CrI: US$161 to 415
230 mon cause of complications during Plasmodium vivax malaria treatment in individuals with glucose 6-ph
233 he incidence rate of symptomatic recurrent P vivax malaria was 0.18 (95% CI 0.15 to 0.21) recurrences
234 esunate-mefloquine (AS-MQ) for uncomplicated vivax malaria was conducted in 3 district hospitals in S
235 hlorproguanil-dapsone for the treatment of P vivax malaria was conducted in eastern Afghanistan and n
241 of which were in hospitalized patients with vivax malaria, we estimated the proportion of patients w
242 althcare provider and household costs due to vivax malaria were collated and combined with national c
243 tan and 452 in Afghanistan) with confirmed P vivax malaria were enrolled and followed up daily for 4
246 an estimated 14 million cases of Plasmodium vivax malaria were reported from Asia, Central and South
249 equally effective in both P falciparum and P vivax malaria, with median parasite clearance half-lives
251 land-Myanmar border had recurrent Plasmodium vivax malaria within 63 days, compared with 18 of 429 pa
253 A successful vaccine against Plasmodium vivax malaria would significantly improve the health and